IP Library Granted Patent US 9,045,761
Granted Patent B2
US 9,045,761 · App. 13/711,482 · Granted Jun 2, 2015

Regulated genetic suicide mechanism compositions and methods

Inventors: Matthew J Giacalone (San Diego, CA); Stanley Maloy (San Diego, CA); Shingo Tsuji (National City, CA)
Assignee: Vaxiion Therapeutics, LLC
C12N15/74C12N1/08C12N9/22C12N15/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,045,761
App. No.
13/711,482
Granted
Jun 2, 2015
Kind
B2
Abstract

Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.

Claims (18)

1. A minicell-producing bacteria, comprising

an expressible cell division gene, wherein the cell division gene is ftsZ, sulA, ccdB, or sfiC; and

an expressible gene encoding a homing endonuclease, wherein the homing endonuclease gene is a transgene,

wherein the chromosome of the minicell-producing bacteria comprises one or more recognition sites of the endonuclease.

2. The minicell-producing bacteria of claim 1 , wherein the minicell-producing gene is a transgene.

3. The minicell-producing bacteria of claim 1 , wherein the cell division gene is ftsZ.

4. The minicell-producing bacteria of claim 1 , wherein the cell division gene is expressed under the control of an inducible promoter.

5. The minicell-producing bacteria of claim 4 , wherein the promoter is inducible by the presence of one or more chemical compounds.

6. The minicell-producing bacteria of claim 1 , wherein the endonuclease gene is located on the chromosome of the minicell-producing bacteria.

7. The minicell-producing bacteria of claim 1 , wherein the homing endonuclease is selected from the group consisting of I-CeuI, PI-Scel, I-ChuI, I-CpaI, I-SceIII, I-CreI, I-MsoI, I-SceII, I-SceIV, I-CsmI, I-DmoI, I-PorI, PI-TliI, PI-TliII, and PI-ScpI.

8. The minicell-producing bacteria of claim 7 , wherein the endonuclease is I-CeuI.

9. The minicell-producing bacteria of claim 1 , wherein the homing endonuclease is expressed under the control of an inducible promoter.

10. The minicell-producing bacteria of claim 9 , wherein the inducible promoter is a temperature-sensitive promoter.

11. The minicell-producing bacteria of claim 1 , wherein the minicell-producing bacteria is a Gram-negative bacteria.

12. The minicell-producing bacteria of claim 11 , wherein the Gram-negative bacteria is selected from the group consisting of Campylobacter jejuni, Lactobacillus spp., Neisseria gonorrhoeae, Legionella pneumophila, Salmonella spp., Shigella spp., Pseudomonas aeruginosa , and Escherichia coli.

13. The minicell-producing bacteria of claim 11 , comprising a gene encoding a gene product that is involved in lipopolysaccharide synthesis, wherein the gene is genetically modified compared to a corresponding wild-type gene.

14. The minicell-producing bacteria of claim 13 , wherein the gene is a msbB gene that encodes a gene product that causes the bacteria to produce an altered lipid A molecule compared to lipid A molecules in a corresponding wild-type bacteria.

15. The minicell-producing bacteria of claim 14 , wherein the altered lipid A molecule is deficient with respect to the addition of myristolic acid to the lipid A portion of the lipopolysaccharide molecule compared to lipid A molecules in a corresponding wild-type bacteria.

Assignments (1)
ORGANIZATION CONVERSION Recorded Apr 30, 2015
From: VAXIION THERAPEUTICS, INC.
To: VAXIION THERAPEUTICS, LLC
Reel/Frame 035557/0644 →
Continuity (4)
Continuation 12490273 · Jun 23, 2009
Provisional Application 61075687 · Jun 25, 2008
Provisional Application 61168457 · Apr 10, 2009
Related Publication 20130210121A1 · Aug 15, 2013